Formulation Development
EXECUTIVE INTERVIEW - Tedor Pharma, Inc.: A Strategy Shift to Serve Both Generic & Branded Companies
Doug Drysdale, President & CEO of Tedor Pharma, Inc., discusses the FLEXITAB technology, his strategy for managing a shift in business model, and how Tedor is addressing the needs of small- and medium-size companies developing innovative and repurposed small molecules for unmet medical needs.
NATURAL LANGUAGE PROCESSING - How Life Sciences Companies Are Leveraging NLP From Molecule to Market
Jane Z. Reed, PhD, MA, discusses some of the challenges facing pharma researchers and executives; the benefit NLP can bring; and some specific customer-use cases (covering patent landscaping, gene disease associations, access to safety silos, and more).
DEVELOPMENT TIMELINES - Drug Development Times, What it Takes - Part 3
Josef Bossart, PhD, analyzes the development and review times of the US FDA’s new drug approvals (NDA and BLA) for the period of 2010 through 2018.
MARKET BRIEF - Allergic Rhinitis Immunotherapy: Opportunity Analysis & Forecasts to 2028
Rose Joachim, PhD, indicates that while a wide variety of OTC therapies exist for the temporary abatement of AR symptoms, allergen-specific immunotherapy is the only truly disease-modifying therapy available for AR.
GLOBAL REPORT – 2019 Global Drug Delivery & Formulation Report: Part 2, Notable Drug Delivery & Formulation Product Approvals of 2019
In part 2 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on notable drug delivery and formulation product approvals.
Lonza Launches New TheraPEAK SfAAV Medium to Boost & Optimize the Production of AAV in Sf9 Insect Cells
Lonza recently announced the launch of the TheraPEAK SfAAV Medium, the first chemically defined, non-animal origin medium designed specifically for the production of….
Derm-Biome Pharmaceuticals Reports Positive Results From a Preclinical Study
Derm-Biome Pharmaceuticals, Inc. recently announced that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of….
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate From Premas Biotech
Akers Biosciences, Inc. recently announced it has acquired a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by…..
WPD Pharmaceuticals Partners With CNS Pharmaceuticals on Drug Development for Coronavirus & Other Antiviral Indications
WPD Pharmaceuticals Inc. recently announced it has entered into a development agreement with CNS Pharmaceuticals, Inc. for the development of……
Novavax’s NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Novavax, Inc. recently announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its…
SPI Pharma Expands Product Portfolio to Support Development, Manufacture & Administration of Oral Dosage Forms
SPI Pharma recently announced an expansion of its line of Mannogem Mannitol products for use in multiple patient-friendly oral dosage forms to now include: Mannogem…
Positive Update on the Development of New XF‐Platform Drug Formulations
Destiny Pharma recently announced the completion of the initial phase of its project with MedPharm to develop new topical formulations of the company’s novel XF‐platform…
Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial
Rafael Pharmaceuticals, Inc. recently announced it has enrolled more than 75% of the 500 patients needed for its pivotal Phase 3 clinical trial for metastatic…
Origin Files Patent Application to Protect its Proposed Treatment for Viral & Bacterial Respiratory Infections
Origin, Inc. recently announced it has filed a provisional US patent application to enhance the ability of its plasma-generated nitric oxide (NO) antimicrobial and antiviral…
Immunogenesis Contracts ProBioGen for Development & Large-Scale Manufacturing Services
ProBioGen AG recently announced that Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, University of Texas, has signed a Service Agreement for Cell…
Enlivex Announces Positive Final Safety & Efficacy Data From Clinical Trial
Enlivex Therapeutics Ltd. recently announced positive final safety and efficacy data from the company’s completed Phase 1b clinical trial in patients with severe sepsis. The…
Catalent Partners With Biohaven on New Fast-Dissolve Treatment
Catalent recently welcomed the announcement by Biohaven Pharmaceutical Holding Company Ltd. that the US FDA has approved its NURTEC ODT (rimegepant) for the acute treatment…
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials
Arcutis Biotherapeutics, Inc. recently announced that, at the request of the US FDA, it has submitted a protocol amendment to the FDA to include children…
CERo Therapeutics Announces Research Collaboration With Lyell Immunopharma; Completion of Financing
Under the terms of the agreement, CERo and Lyell will collaborate to pursue proof-of-concept studies for a new class of cell-based therapeutics directed against….
Evonik Achieves Major Biotech Breakthrough With a New Animal-Free & Fermentation-Based Collagen Platform
Evonik recently announced the development of an advanced collagen platform that is made via fermentation-based processes and devoid of animal- or human-derived materials…..
